Health Check: On Garfield the Cat Day, the biotech sector purrs with deals and breakthroughs
Singular Health inks US physician network deal
Clarity clearly is undervalued, say brokers
Among other auspicious events, the 19th of June marks the end of slavery in the US, Garfield the Cat Day and the birthdays of former British PM Boris Johnson and royal temptress Wallis Simpson.
So why not add a slew of meaningful life sciences announcements, including an HIV vaccine breakthrough, to the June 19 pantheon?
Let's start with Orthocell (ASX:OCC), which reports 'compelling data' showing its Remplir nerve repair agent is superior to suture-only standard techniques.
Stitching accounts for circa 90% of the 700,000 nerve repair procedures done in the US annually.
A cuff that envelops the damaged peripheral nerves, Remplir reduces the use of stitching, which can compromise nerve repair.
Orthocell's study used a rat sciatic nerve injury model, covering 48 rodents across four treatment groups.
These cohorts covered repairs using one, three or six sutures, compared with one suture augmented with Remplir.
The rats' nerve function and regeneration were evaluated up to 12 weeks post-treatment.
The FDA ticked off Remplir in early April and the device is also approved in Canada, Hong Kong, Singapore, New Zealand and here.
Thus, the study was pitched not so much as approval as supporting the US sales rollout.
Orthocell cites a total addressable market in its target markets of US$3.5 billion, with its already-approved geographies accounting for US$1.8 billion.
The US market is worth US$1.6 billion.
Stem-cell hope for bone marrow transplant patients
NeuroScientific Biopharmaceuticals (ASX:NSB) highlights previous clinical data showing its soon-to-be acquired stem cell platform is effective in preventing graft-versus-host disease (GvHD).
The company is buying the asset, Stemsmart from the unlisted Perth-based Isopogen.
The phase I work covered adults and children with life-threatening, steroid-resistant GvHD, a common complication of bone-marrow transplants.
The data shows the treatment is safe and well tolerated, 'with no infusion related toxicities'.
Furthermore, most adults and children had a 'complete or partial resolution of symptoms and improved survival'.
Of the 10 children treated on compassionate grounds, all had survived 12 months post implant. Three of them were still alive six years post treatment.
Turning to pancreatic cancer, Amplia (ASX:ATX) reports another patient with a 'complete response' in its 55-patient trial dubbed Accent.
As close as dammit to a cure, a confirmed complete response formally is defined as all tumour lesions disappearing, with the effect maintained for at least two months.
'This is a rare outcome in advanced pancreatic cancer where the disease has spread to other parts of the body,' the company says.
A Singularly fine US deal
Imaging medtech outfit Singular Health Group Ltd (ASX:SHG) has signed a $2 million agreement with a US physician network to develop and use Singular's 3Dicom medical imaging tool.
The compact is with Provider Network Solutions (PNS), covering physician networks in Puerto Rico, Florida, and Texas.
It covers the initial deployment of 1000 3Dicom licences, at US$800 each.
Singular pockets a further US$500,000 on 'satisfaction of AI model marketplace and image repository development and integration'.
The company hope to expand to the remaining 30 states that PNS covers.
3Dicom converts magnetic resonance imaging and computed tomography scans to enable 'immersive visualisation' with three-dimensional images.
Singular also said it had received $8 million of firm commitments in its recently-announced placement.
Meanwhile, microbiome testing house Microba Life Sciences (ASX:MAP) is on trading halt pending a capital raising.
EZZ girds for US launch
Hitherto China and locally focused, health supplements outfit EZZ Life Science (ASX:EZZ) has launched four initial products into the US after winning FDA approval.
To be sold under the new Ezzday banner, the products are made in the US and are tailor-made for American consumers.
Seeing you asked, the remedies cover de-bloating/de-gassing, vaginal probiotics, skincare and colon detox. Readers can draw their own conclusions as to what that means about the State of the Nation in Trumpian times.
Initially, the products will be sold via Amazon and Shopify.
Locally EZZ sells via more than 600 chemists and globally via 750 ecommerce platforms, including China's Douyin and Tmall.
The company values the US supplements market at US$100 billion a year, pipping China's US$80 billion opportunity.
US health secretary Robert F Kennedy Junior (RFK Jr) has a special interest in health supplements, which at the very least shouldn't harm EZZ's US ambitions.
EZZ shares have been on a tear – up 33% over the last month – but they are still well shy of the record $5 peak in October last year.
HIV jab spells hope for end to '45-year pandemic'
Speaking of RFK Jr, the FDA has approved a drug that is meant to protect against HIV with a single administration every six months.
Yep – it's a vaccine – so maybe the health czar isn't as avowedly anti-vaxx as we all think.
Marketed as Yeztugo by Gilead Sciences, lenacapavir is seen as the best hope of knocking HIV – in effect a 45-year pandemic – on its head.
Clinicians say the drug is much more powerful than the current oral treatments and almost 100% effective.
'This is a historic day in the decades-long fight against HIV,' Gilead CEO Daniel O'Day said.
'Yeztugo is one of the most important scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic.'
The drug has a list price of US$28,218 ($43,300). But Gilead may provide the vaccine free to non-insured patients.
Have investors underestimated Clarity?
Is radiopharmacy outfit Clarity Pharmaceuticals (ASX:CU6) a case of 'objects in this rear view mirror are closer than you think'?
Following a series of clinical updates from Clarity, broker Canaccord values the company at $6.74 a share, a lofty 210% increment on the current price.
In March, Wilsons ascribed an even ballsier $8.25 a share.
All things being equal – and they never are – that would value Clarity at $2.6 billion.
Sector champ Telix Pharmaceuticals (ASX:TLX) is worth around $8 billion, bearing in mind it has two FDA-approved prostate cancer imaging tools and a kidney cancer consent in the offing.
Yesterday, Clarity said it has struck an agreement with US mob Spectronrx.
Spectronrx will provide 400,000 patient-ready does of its copper isotope based 64Cu-SAR-bisPSMA (for diagnosing and potentially treating prostate cancer).
In the nuclear medicine game, gaining access to nearby doses is half the battle. But this agent's generous half-life means it can be distributed across all 50 US states.
Clarity recently announced promising phase II results for 64Cu-Sartate (neuroblastoma) and 64Cu-SAR-Bombesin (PSMA-negative prostate cancer).
Another program, Secure, focuses on identifying and treating metastatic castration-resistant prostate cancer.
Clarity currently has no approved products, but Canaccord expects 64Cu-SAR-bisPSMA to be on market by mid 2027.
'Recent commercial agreements should remind the market that this potential best-in-class asset could be closer than we think.'
The firm reckons Clarity can win a 20% share of the US market, for US$520m in peak sales.
Your columnist's nuclear science credentials – the ones plucked from a Weeties pack – are out of date.
But it looks like Telix should have one eye on the rear-view mirror and the other on the road ahead.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
3 hours ago
- News.com.au
‘This is very big': Delighted Trump hails Australian beef deal for a second day
Donald Trump has again riffed about Australia's decision to allow more US beef to come in to the country claiming on Friday it would be the 'first time' American beef would be sold in Australia. Seemingly out of the blue on Friday, and a full day after he declared victory due to Australia dropping its restrictions, Mr Trump was back on his TruthSocial platform talking about it again. 'Australia to take US BEEF for first time,' he wrote on Friday morning, US time. 'A very BIG market. I hope our GREAT FARMERS ARE HAPPY. MAKE AMERICA GREAT AGAIN!!!' Australia had not banned US beef. But on Thursday, agriculture minister Julie Collins confirmed Australia will remove the ban on American beef that came from cattle originating in Canada and Mexico after a decade-long review. It was originally put in place to stop bovine spongiform encephalopathy, known as mad cow disease, from coming into Australia. Since 2019, Australia has allowed imports of beef raised and slaughtered in the US. But it did not allow for the import into Australia via the US of beef raised in neighbouring countries. Additional measures put in place by the US to track the origin of Canadian and Mexican beef are being cited as the reason Australia is now satisfied. 'For a long time, and even though we are great friends, they actually banned our Beef,' said Mr Trump on Thursday, US time. Now, we are going to sell so much to Australia because this is undeniable and irrefutable Proof that US Beef is the Safest and Best in the entire World.' The US imports billions of dollars of Australian beef each years which is leaner than American beef. Decision based on 'science' The Albanese government has been quick to deny the timing has anything to do with drawn-out tariff talks with the US, reported NewsWire. But removing restrictions was one of Washington's key demands in tariff negotiations, with Mr Trump specifically accusing Australia of banning American beef during remarks on 'liberation day' – the day the US imposed blanket tariffs on all foreign imports, including Australian products. But both Ms Collins and Trade Minister Don Farrell have claimed it is simply a coincidence the beef review ended just weeks after the US President threatened a 200 per cent tariff on foreign-made pharmaceuticals. 'We haven't made any compromise, and we certainly haven't compromised Australia's strict biosecurity laws,' Senator Farrell told reporters huddled in a Parliament House corridor on Thursday. 'This has been a process that's been underway for the last 10 years. 'It's now come to a completion, and it's appropriate that we announce the results of that inquiry, but at no stage do we risk our terrific biosecurity standards for any trade arrangement.'
The Age
a day ago
- The Age
The properties about to test Collingwood's cool credentials
The US fund bought the 22-storey building from Challenger at a serious premium in 2019. Challenger, which paid $81 million in 2011, held the tower on its books at $165 million. At the time of AEW's off-market purchase, the 19,213 sq m building was raking in $10 million a year in rent giving the deal a tight 4.9 per cent yield. While not giving much away, AEW says it has achieved a 52.8 per cent increase in rental income in the six years it has owned the tower. It's understood that's on a fully leased basis, and the tower's occupation rate is currently about 83 per cent with new tenants still taking up space. CBRE's Kiran Pillai, Scott McGlone and Nikola Jackson with Cushman & Wakefield's Leigh Melbourne, Nick Rathgeber, Josh Cullen and Morgan Briscoe have charge of the listing. 'Thirty-one Queen Street has been a dominant performer in the leasing market over the past three to four years, underpinned by one of the best examples of a ground-up refurbishment,' Pillai said. 'Given the asset's exceptional fundamentals, central-CBD location and low-risk cashflow, we expect strong interest from high-net-worth privates, syndicators and funds,' Melbourne said. The decline in CBD values appears to have bottomed out with a series of big-game bargain hunters, ranging from cashed-up locals to offshore behemoths lured back to the market. Hong Kong private equity property company PAG is understood to be running the ruler over Dexus' Flinders Gate complex. Its current book value stands at $265.5 million with Dexus is reportedly hoping for around $260 million. Last year PAG snagged 367 Collins Street for $340 million from Mirvac, a 20 per cent discount to its peak value. The move also comes as Singapore-listed Frasers Logistics & Commercial Trust revealed it had sold 357 Collins Street to Harry Stamoulis for $195.3 million. The final price – about current book value – will clock in at $192 million, after lease incentive liabilities are paid out. Frasers paid a staggering $222.5 million 10 years ago. Heavy lifting on High Developers are expected to swoop on a huge building on Armadale's swanky High Street. The building which houses Armadale's Goodlife Gym at 1216-1230 High Street, comes with a price guide of $25-$30 million. The property is on a 1926 sq m parcel of land stretching back to Willis Street at the rear. Records show the Tauber family paid $1.62 million for the property in 1986. The gym includes a pool. Packed to the eyeballs with frock shops, bridal boutiques, cafes and homewares, High Street has a vacancy rate of just 2.3 per cent, according to Fitzroys' retail vacancy report, Walk the Strip, with rents commanding as much as $2000 a square metre. Last year, the auction of 1047-1051 High Street dragged on for two hours with 900 bids volleyed between two parties. The corner double-storey office and shop, on 500 sq m of land, eventually sold for $11.4 million. The Goodlife building is for sale through Cushman & Wakefield's Daniel Wolman, Oliver Hay, Hamish Burgess and Leon Ma with Teska Carson's Matthew Feld. There's a bit of choice on the strip at the moment. Lawyer and investor Peter Mitrakas is selling a 1585 sq m parcel of land at 23-27 Osment Street near Armadale Station for about $20 million. And five strata owners at 1097-1111 High Street are hoping to sell their building – on a large 1733 sq m site on the corner of Huntingtower Road – for about $30 million. East Melbourne A local private investor has paid about $13.5 million for the old Melbourne IVF fertility clinic at 344 Victoria Parade, a much-storied building in East Melbourne's medical precinct which won awards when it was built in the early 1990s. While the vendor, veteran investment group Henkell Brothers, was seeking closer to $15 million for the three storey-office, it nonetheless made a tidy profit. Henkell Brothers bought the 2444 sq m building from the late Richard Pratt's Pratt Industries in 1995 for just $3.92 million – after it passed in at a mortgagee auction for $2.9 million. It was a bargain even at the time. The Victorian Public Service Association had been ready to pay $7.12 million for the city-fringe office, but the deal fell through after the sale of its CBD office to theatre impresario David Marriner collapsed. CBRE agents Nick Peden, Sandro Peluso, Jamus Campbell and Mark Granter negotiated the deal. 'The campaign attracted significant interest, with several unconditional offers received from both local and international investors – an unprecedented result for a vacant property,' Peden said. The building had been the home of Melbourne IVF's fertility clinic for many years but the baby-maker is off to Hines' new 15-storey timber building, T3 at 36 Wellington Street, across the road. AirHub Growthpoint Properties is testing the market's appetite for industrial investments offering up a six-property portfolio at Melbourne Airport. The AirHub portfolio, currently on Growthpoint's books with a $127 million value, covers a 25-hectare chunk of land around the airport with net lettable space of 139,707 sq m. They're being offered individually or as a job lot. Tenants include Australia Post, Unipart Group, Direct Couriers and Laminex.
Sydney Morning Herald
a day ago
- Sydney Morning Herald
The properties about to test Collingwood's cool credentials
The US fund bought the 22-storey building from Challenger at a serious premium in 2019. Challenger, which paid $81 million in 2011, held the tower on its books at $165 million. At the time of AEW's off-market purchase, the 19,213 sq m building was raking in $10 million a year in rent giving the deal a tight 4.9 per cent yield. While not giving much away, AEW says it has achieved a 52.8 per cent increase in rental income in the six years it has owned the tower. It's understood that's on a fully leased basis, and the tower's occupation rate is currently about 83 per cent with new tenants still taking up space. CBRE's Kiran Pillai, Scott McGlone and Nikola Jackson with Cushman & Wakefield's Leigh Melbourne, Nick Rathgeber, Josh Cullen and Morgan Briscoe have charge of the listing. 'Thirty-one Queen Street has been a dominant performer in the leasing market over the past three to four years, underpinned by one of the best examples of a ground-up refurbishment,' Pillai said. 'Given the asset's exceptional fundamentals, central-CBD location and low-risk cashflow, we expect strong interest from high-net-worth privates, syndicators and funds,' Melbourne said. The decline in CBD values appears to have bottomed out with a series of big-game bargain hunters, ranging from cashed-up locals to offshore behemoths lured back to the market. Hong Kong private equity property company PAG is understood to be running the ruler over Dexus' Flinders Gate complex. Its current book value stands at $265.5 million with Dexus is reportedly hoping for around $260 million. Last year PAG snagged 367 Collins Street for $340 million from Mirvac, a 20 per cent discount to its peak value. The move also comes as Singapore-listed Frasers Logistics & Commercial Trust revealed it had sold 357 Collins Street to Harry Stamoulis for $195.3 million. The final price – about current book value – will clock in at $192 million, after lease incentive liabilities are paid out. Frasers paid a staggering $222.5 million 10 years ago. Heavy lifting on High Developers are expected to swoop on a huge building on Armadale's swanky High Street. The building which houses Armadale's Goodlife Gym at 1216-1230 High Street, comes with a price guide of $25-$30 million. The property is on a 1926 sq m parcel of land stretching back to Willis Street at the rear. Records show the Tauber family paid $1.62 million for the property in 1986. The gym includes a pool. Packed to the eyeballs with frock shops, bridal boutiques, cafes and homewares, High Street has a vacancy rate of just 2.3 per cent, according to Fitzroys' retail vacancy report, Walk the Strip, with rents commanding as much as $2000 a square metre. Last year, the auction of 1047-1051 High Street dragged on for two hours with 900 bids volleyed between two parties. The corner double-storey office and shop, on 500 sq m of land, eventually sold for $11.4 million. The Goodlife building is for sale through Cushman & Wakefield's Daniel Wolman, Oliver Hay, Hamish Burgess and Leon Ma with Teska Carson's Matthew Feld. There's a bit of choice on the strip at the moment. Lawyer and investor Peter Mitrakas is selling a 1585 sq m parcel of land at 23-27 Osment Street near Armadale Station for about $20 million. And five strata owners at 1097-1111 High Street are hoping to sell their building – on a large 1733 sq m site on the corner of Huntingtower Road – for about $30 million. East Melbourne A local private investor has paid about $13.5 million for the old Melbourne IVF fertility clinic at 344 Victoria Parade, a much-storied building in East Melbourne's medical precinct which won awards when it was built in the early 1990s. While the vendor, veteran investment group Henkell Brothers, was seeking closer to $15 million for the three storey-office, it nonetheless made a tidy profit. Henkell Brothers bought the 2444 sq m building from the late Richard Pratt's Pratt Industries in 1995 for just $3.92 million – after it passed in at a mortgagee auction for $2.9 million. It was a bargain even at the time. The Victorian Public Service Association had been ready to pay $7.12 million for the city-fringe office, but the deal fell through after the sale of its CBD office to theatre impresario David Marriner collapsed. CBRE agents Nick Peden, Sandro Peluso, Jamus Campbell and Mark Granter negotiated the deal. 'The campaign attracted significant interest, with several unconditional offers received from both local and international investors – an unprecedented result for a vacant property,' Peden said. The building had been the home of Melbourne IVF's fertility clinic for many years but the baby-maker is off to Hines' new 15-storey timber building, T3 at 36 Wellington Street, across the road. AirHub Growthpoint Properties is testing the market's appetite for industrial investments offering up a six-property portfolio at Melbourne Airport. The AirHub portfolio, currently on Growthpoint's books with a $127 million value, covers a 25-hectare chunk of land around the airport with net lettable space of 139,707 sq m. They're being offered individually or as a job lot. Tenants include Australia Post, Unipart Group, Direct Couriers and Laminex.
